MarketPulse

clinical-stage biopharmaceutical

9 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Nrx Pharmaceuticals, Inc.

NRx Pharmaceuticals to Unveil 2025 Results, Update on Breakthrough Psychiatric Drug Pipeline

NRx Pharmaceuticals to report 2025 results March 24, 2026, updating on FDA-designated ketamine and PTSD programs with significant clinical potential.
NRXPNRXPWfinancial resultsclinical-stage biopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

OKYO Pharma CDO Backs Pipeline With $49K Share Purchase as Phase 2b/3 Trial Looms

OKYO Pharma's Chief Development Officer purchases 30,980 shares at $1.59, signaling confidence in urcosimod as company prepares Phase 2b/3 trial launch in H1 2026.
OKYOclinical-stage biopharmaceuticalneuropathic corneal pain
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Neumora to Unveil 2025 Results as Pipeline Advances Toward Critical Trial Readouts

Neumora Therapeutics will report 2025 financial results March 30, 2026, with major KOASTAL trial readouts anticipated in Q2 2026.
NMRAfinancial resultsclinical-stage biopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Minerva Neurosciences, Inc.

Minerva Neurosciences Posts $293M Loss But Bolsters Cash Reserves for Schizophrenia Drug Trial

Minerva Neurosciences reported $293.4M FY2025 net loss, largely from non-cash charges. The biotech secured $80M funding and plans Phase 3 roluperidone trial launch in Q2 2026.
NERVprivate placementPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Actuate Therapeutics to Unveil Cancer Pipeline Expansion at Citizens Conference

Actuate Therapeutics plans to present at the Citizens Life Sciences Conference on March 10, advancing elraglusib tablet into Phase 1/2 oncology trials launching H2 2026.
ACTUcancer therapypipeline expansion
GlobeNewswire Inc.GlobeNewswire Inc.··Na

MAIA Biotech Raises $30M in Public Offering to Fund Clinical Trials

MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/share, funding clinical trials and operations.
MAIApublic offeringcommon stock
GlobeNewswire Inc.GlobeNewswire Inc.··Na

MAIA Biotech Raises $30M via Stock Offering to Fund Clinical Trials

MAIA Biotechnology prices $30M public offering at $1.50/share to fund clinical trials. Offering closes March 4, 2026.
MAIApublic offeringcommon stock
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Bicara Therapeutics Raises $150M Through Stock and Warrant Offering

Bicara Therapeutics raises $150M through stock and warrant offering to fund lead drug candidate development, expand manufacturing, and build commercial infrastructure.
BCAXEGFRpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Strengthens Balance Sheet With $172.5M Offering; Eyes Mid-2027 Cash Runway

Inventiva raises $172.5M, strengthening balance sheet to €230.9M in liquidity. Clinical-stage biotech projects cash runway through mid-2027 to advance MASH treatment program.
IVApublic offeringclinical-stage biopharmaceutical